MedTrace Logo

Evaluate the Safety and Efficacy of HG102 as Compared to Botox® in Subject With Moderate to Severe Glabellar Lines

NCT05801146 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 272

Last updated 2024-01-16

No results posted yet for this study

Summary

To evaluate the efficacy and safety of HG102 for moderate to severe Glabellar Lines, non-inferiority compared to Botox® was confirmed and safety was evaluated.

Conditions

  • Glabellar Lines

Interventions

DRUG

Botulinum Toxin Type A Injection [HG102]

Single administration, Day 0, 20 units

DRUG

Botulinum Toxin Type A Injection [Botox]

Single administration, Day 0, 20 units

Sponsors & Collaborators

  • Hugel

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-04
Primary Completion
2025-03-31
Completion
2025-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05801146 on ClinicalTrials.gov